特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

代謝型グルタミン酸受容体2 (mGluR2、GRM2、GPRC1B、MGLUR2):パイプライン製品の分析

Metabotropic Glutamate Receptor 2 - Pipeline Review, H1 2020

発行 Global Markets Direct 商品コード 363567
出版日 ページ情報 英文 53 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.71円で換算しております。
代謝型グルタミン酸受容体2 (mGluR2、GRM2、GPRC1B、MGLUR2):パイプライン製品の分析 Metabotropic Glutamate Receptor 2 - Pipeline Review, H1 2020
出版日: 2020年05月30日 ページ情報: 英文 53 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

当レポートでは、世界各国でのグルタミン酸受容体2 (別名mGluR2、GRM2、GPRC1B、MGLUR2) 治療薬のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

  • イントロダクション
    • 分析範囲
  • 代謝型グルタミン酸受容体2 (mGluR2、GRM2、GPRC1B、MGLUR2) の概要
  • 治療薬の開発状況
    • 治験の段階別
    • 治療領域別
    • 症状別
  • パイプライン製品の概略
    • 後期段階の製品
    • 初期段階の製品
  • 各企業で開発中の治療薬
  • 各大学・研究機関で開発中の治療薬
  • 治療薬の評価
    • 単剤治療薬/併用治療薬の場合
    • 作用機序別
    • 投与方法別
    • 分子の種類別
  • 治療薬の開発に従事している企業
    • Addex Therapeutics Ltd
    • Domain Therapeutics SA
    • Eli Lilly and Company
    • Johnson & Johnson
    • Merck & Co., Inc.
    • 大正製薬ホールディングス
  • 薬剤のプロファイル
  • 開発が休止状態の製品
  • 開発が中止された製品
  • 注目すべき最新動向・プレスリリース
  • 付録

図表一覧

図表

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Addex Therapeutics Ltd, H1 2020
  • Pipeline by Bristol-Myers Squibb Co, H1 2020
  • Pipeline by Camino Pharma LLC, H1 2020
  • Pipeline by Denovo Biopharma LLC, H1 2020
  • Pipeline by Eli Lilly and Co, H1 2020
  • Pipeline by Johnson & Johnson, H1 2020
  • Pipeline by Merck & Co Inc, H1 2020
  • Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2020
  • Dormant Products, H1 2020
  • Dormant Products, H1 2020 (Contd..1), H1 2020
  • Dormant Products, H1 2020 (Contd..2), H1 2020
  • Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
目次
Product Code: GMDHC2428TDB

Summary:

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report Metabotropic Glutamate Receptor 2 - Pipeline Review, H1 2020, outlays comprehensive information on the Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Metabotropic glutamate receptor 2 is a protein encoded by the GRM2 gene. It is a receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. May mediate suppression of neurotransmission or may be involved in synaptogenesis or synaptic stabilization. The molecules developed by companies in Phase I and Preclinical stages are 3 and 6 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Depression, Schizophrenia, Drug Addiction, Alzheimer's Disease, Anxiety Disorders, Epilepsy, Mild Cognitive Impairment, Nicotine Addiction, Panic Disorders, Parkinson's Disease, Post-Traumatic Stress Disorder (PTSD), Psychosis and Treatment Resistant Depression.

Furthermore, this report also reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)
  • The report reviews Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Overview
    • Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Bristol-Myers Squibb Co
    • Camino Pharma LLC
    • Denovo Biopharma LLC
    • Eli Lilly and Co
    • Johnson & Johnson
    • Merck & Co Inc
    • Taisho Pharmaceutical Holdings Co Ltd
  • Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Drug Profiles
    • BMT-133218 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-40411813 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Dormant Products
  • Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Discontinued Products
  • Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer